United States · Who invested in Talaris Therapeutics?
Talaris Therapeutics's investors include Blackstone Life Sciences, Qiming Venture Partners and Longitude Capital. Blackstone Life Sciences led its latest round.
United States · Series A startup
Who invested in Talaris Therapeutics
Funding summaryUpdated 26 Oct 2026
$100Mraised across 1 round since 2019, from 1 source
- Latest round
- Series A, $100MApr 2019
- Led by
- Blackstone Life Sciences
- Investors
- 3 (1 led)
The rounds
- Apr 2019Series A$100M
- Blackstone Life SciencesLead
Qiming Venture Partners
Longitude Capital
Reported by FinSMEs
Founders and team
From the SEC filings it signed: 2 on the team.
- Scott RequadtExecutive Officer, Directori
- Suzanne IldstadExecutive Officer, Directori
On the board, as filediFrancois NaderGeoff MackayMark McDadeNick GalakatosSandip Agarwala
Everyone who backed them
Blackstone Life Sciencesno record of our own yet1round, led 1
Missing a round, or an investor who was in one? Tell us.
Quick answers about Talaris Therapeutics
How much has Talaris Therapeutics raised?
Talaris Therapeutics has raised $100M across 1 round since 2019.
When did Talaris Therapeutics last raise?
Talaris Therapeutics's most recent round was a Series A of $100M in Apr 2019, led by Blackstone Life Sciences.
What was Talaris Therapeutics's biggest round?
Its most recent round, $100M in Apr 2019, is also its largest on record.
Who backed Talaris Therapeutics first?
Talaris Therapeutics's first round on record, in Apr 2019, was backed by Blackstone Life Sciences, Qiming Venture Partners and Longitude Capital.
What stage is Talaris Therapeutics at?
Talaris Therapeutics's latest named round is a Series A, in Apr 2019.
Where is Talaris Therapeutics based?
Talaris Therapeutics is based in the United States.
Who led Talaris Therapeutics's rounds?
Blackstone Life Sciences led the Series A in 2019.
Companies like Talaris Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.